一个脱水-扩散竞争框架预测了高度生物填充-完成的界面膜风险.
Yu-Jiun Lin1, Ruomeng Qiu1, Qi Gao1
1Development Science & Clinical Supply, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Molecular pharmaceutics
|November 16, 2025
概括
在填充完成操作期间过渡性脱水会导致高度蛋白质配方形成不可逆转的膜. 本研究定义了用于预测和预防这些问题的关键指标,以确保制造业的成功.
科学领域:
- 生物制药制造业 生物制药制造业
- 蛋白质配方科学 蛋白质配方科学
- 类风病学 类风病学 类风病学
背景情况:
- 高度蛋白质配方对于皮下注射至关重要,提供临床和商业效益.
- 然而,这些配方在制造过程中容易脱水,导致残留物形成和像堵塞的针一样的操作故障.
- 过渡性脱水会产生表面粘弹性膜,抵抗再溶解并阻碍药物递送性能.
研究的目的:
- 建立一个操作框架,将脱水暴露与薄膜力学和高度生物制剂的可逆性联系起来.
- 确定关键参数和值,以防止在填充完成过程中不可逆转的薄膜形成.
- 根据配方特性和脱水条件,制定停机时间和重新湿策略的定量限制.
主要方法:
- 使用一台具有控制空气流量的长椅尺寸装置研究脱水对蛋白质配方的影响.
- 测量界面粘弹性特性,包括储存模量 (G),作为累积质量损失的函数.
- 定义并使用了四种便携式读数:最大薄膜强度 (GM),最终薄膜强度 (GF),浸泡时间 (tImb) 和溶解时间 (tDis).
主要成果:
- 观察到,随着质量损失的增加,界面存储模块 (G") 的数量增加.
- 确定了两个关键的包装值:随机松散包装 (RLP,~0.56) 和随机密封包装 (RCP,~0.64),这影响了膜机械和动力学.
- 确定了临界质量损失窗口 (~52-55%),与最终薄膜强度的急剧增加和过程时间尺度上的条件不可逆转性相关.
结论:
- 为高度蛋白质配方开发了定量框架和可操作的"无膜/有风险"地图.
- 该地图以脱水流量,时间和配方属性进行索引,为流程优化提供关键见解.
- 这些发现为制造停机时间提供了定量限制,并提出了用于减轻填充完成操作中不可逆转的薄膜形成的重新湿策略.
相关概念视频
Theories of Dissolution: The Danckwerts' Model and Interfacial Barrier Model
751
Various dissolution theories provide insight into the factors that influence the dissolution rate. Danckwerts' Model suggests that turbulence, rather than a stagnant layer, characterizes the dissolution medium at the solid-liquid interface. In this model, the agitated solvent contains macroscopic packets that move to the interface via eddy currents, facilitating the absorption and delivery of the drug to the bulk solution. The regular replenishment of solvent packets maintains the...
751
Theories of Dissolution: Diffusion Layer Model
1.6K
Dissolution, the process by which drug particles dissolve in a solvent, is explained by the diffusion layer model, a theoretical framework that simulates the absorption of oral drugs and allows us to analyze experimental data.
This process starts with a thin layer, saturated with the drug, forming at the interface between the solid and liquid. The solute then diffuses from this layer into the main solution. The Noyes-Whitney equation suggests that the rate of dissolution relies on the diffusion...
This process starts with a thin layer, saturated with the drug, forming at the interface between the solid and liquid. The solute then diffuses from this layer into the main solution. The Noyes-Whitney equation suggests that the rate of dissolution relies on the diffusion...
1.6K
Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
322
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
322
Drug Distribution: Volume of Distribution
7.0K
The volume of distribution refers to the theoretical volume necessary to contain the entire amount of an administered drug at the same concentration observed in the blood plasma. The body's intracellular fluid compartment, which makes up two-thirds of the total body water, is contrasted with the extracellular fluid compartment—comprising plasma and interstitial fluid—that accounts for one-third. The volume of distribution can vary depending on the characteristics of the drug.
7.0K
Passive Diffusion: Overview and Kinetics
1.2K
Passive diffusion is a critical process that allows small lipophilic drugs to cross the cell membrane along a concentration gradient. This mechanism's efficiency depends on four primary factors: the membrane's surface area, the drug's lipid-water partition coefficient, the concentration gradient, and the membrane's thickness.
When administered orally, drugs establish a substantial concentration gradient between the gastrointestinal (GI) lumen and the bloodstream, expediting...
When administered orally, drugs establish a substantial concentration gradient between the gastrointestinal (GI) lumen and the bloodstream, expediting...
1.2K
Bioavailability Enhancement: Drug Solubility Enhancement
208
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
208


